As a business leader, we reflect on so much of our performance but not the thing that's driving it: our brains. Yet it's our brain anatomy which is truly individualised and unique to each business owner. Without it, our business cannot run. As a cognitive health...
The science, the promise, and the pitfalls The idea of a “metabolic reset” has gained traction across wellness media, social platforms, and weight management programmes. The premise is appealing: that metabolism can be “retrained” or “rebooted” through short-term...
Why comfort and fit are essential design considerations in medical devices In many industries, product design rarely accounts for the variability of user profiles, with a focus on the ‘average’ person. Headphones or even glasses too often do not account for head size...
Why People, Process, and Purpose Matter Most Following a period of experimentation, life sciences is entering a pivotal new phase in AI adoption. The industry is shifting away from hype-driven pilots and toward proven, value-led applications that improve how therapies...
Hormone health expert and bestselling author Dr Louise Newson explains why we'll all be tracking our hormones in 2026. The use of period tracking apps and menopause symptom tracker apps are at an all-time high. And it’s no wonder. These apps can be incredibly useful...
OpenAI is making its most coordinated move into healthcare to date, positioning ChatGPT Health as a central interface for clinical, research, and operational use across the medical ecosystem. Rather than launching a single consumer-facing medical product, the company...
Digital transformation is accelerating across the life sciences sector as more organisations adopt AI driven platforms and cloud computing to speed up drug discovery, streamline clinical trials and optimise operations. A recent industry overview from BioSpace...
Why popEVE Matters Interpreting missense variants has long been one of the most persistent challenges in clinical genetics. These single–amino-acid substitutions can subtly alter protein structure or function, yet their effects are often context-dependent and...
In a landmark development for stroke treatment, medical technology company Remedy Robotics has announced what it describes as the world’s first fully remote endovascular neurointerventional procedures using its N1 robotic system. The announcement, made on 6 October...
Dementia continues to pose a significant challenge in neuroscience and clinical care, affecting millions worldwide. Early detection is pivotal in slowing disease progression and implementing preventive interventions. Life sciences are increasingly leveraging...
The intersection of artificial intelligence (AI) and pharmaceutical research is transforming drug discovery, clinical trials, and healthcare innovation. Leading technology companies Nvidia, Microsoft, and Google are spearheading this evolution, applying advanced AI...
Artificial intelligence company Anthropic is making a significant move into the life sciences sector with the launch of Claude for Life Sciences, a version of its Claude language model platform tailored for scientific research, drug discovery and regulatory workflows....
Microsoft is reportedly preparing a major update to its Copilot AI assistant that will let it draw on licensed medical content from Harvard Health Publishing when responding to user queries about healthcare. The development signals a strategic shift toward embedding...
Medical imaging company Hyperfine, listed on the Nasdaq as HYPR, has announced the pricing of an underwritten public offering of 14 million shares of its Class A common stock at $1.25 per share, yielding gross proceeds of approximately $17.5 million before...